The EyeArt® AI Eye Screening System is the most extensively validated AI technology for autonomous detection of diabetic retinopathy, tested on over half a million patient visits globally with over two million images collected in real-world clinical environments.
* EyeArt® has been cleared for sales as a Class IIa medical device by EU and as a Class 2 medical device by Health Canada.
** In the United States, EyeArt® is limited by federal law to investigational use only and is not available for sale.
How can EyeArt Help?
The EyeArt system provides automated diabetic retinopathy screening without the need for expert human grading or eye dilation, enabling imaging, grading and reporting in a single office visit.
What does EyeArt Do?
The EyeArt system autonomously analyzes patient's retinal images acquired using an integrated fundus camera, robustly detects signs of disease, and returns an easy-to-read report in under 60 seconds.
How does EyeArt Work?
The EyeArt system incorporates a number of deep learning and image analysis algorithms to automatically assess the quality of the images, detect the presence and extent of lesions, and determine level of disease based on internationally recognized clinical scales.
Why choose EyeArt?
The EyeArt system is the world’s most-validated artificial intelligence (AI) screening tool for diabetic retinopathy, demonstrating high real-world sensitivity and specificity. It is proven to be safe, fast, and consistent.
* Claims on this page have not been evaluated by US FDA
Jennifer I. Lim, MD, Marion H. Schenk Esq. Chair, Professor of Ophthalmology, and Director of Retina Service at the University of Illinois at Chicago presented the Eyenuk Clinical Trial study results at the ARVO 2019 Imaging in the Eye Conference in Vancouver, Canada. Dr. Lim spoke to MD Magazine about the study in a 3 part interview series.
Select Collaborators, Customers, & Partners
Eyenuk Receives NIH Grant To Expand AI Eye Screening Platform for Neurodegenerative Disease Detection
LOS ANGELES, Oct. 10, 2019 – Imagine if the very first signs of dementia, before any significant memory or other physiological changes are apparent, could be identified via a simple eye exam. That possibility may...
Largest Peer-Reviewed Study on AI in Health Care Shows Real-World Significance of EyeArt AI Eye Screening System from Eyenuk
Landmark Study of Over 100,000 Diabetes Patient Visits Published in the Journal Diabetes Technology and Therapeutics Validates the Prowess of the EyeArt AI System for Diabetic Retinopathy Screening LOS ANGELES, August 08, 2019 – Eyenuk...
Artificial Intelligence helps identify Diabetic Retinopathy and Clinically Significant Diabetic Macular Edema
July 30, 2019. Chicago, IL: The results of a prospective study, titled “Artificial Intelligence Screening for Diabetic Retinopathy: Analysis from a Pivotal Multi-center Prospective Clinical Trial,” were presented at the 37TH American Society of Retina...
Researchers Study Improvement in Patient Compliance and Screening Efficacy by Using the EyeArt AI Eye Screening System for Detecting Diabetic Retinopathy
LOS ANGELES, June 5, 2019 – Eyenuk Inc., a global artificial intelligence (AI) medical technology and services company and the leader in real-world applications for AI Eye Screening™, announced today that data from scientific studies...
German Diabetes Clinic Increases Diabetic Retinopathy Screenings Provided from Zero to Thousands After Implementing Eyenuk’s EyeArt AI Eye Screening System
LOS ANGELES, CA, May 16, 2019 – Eyenuk, Inc., a global artificial intelligence (AI) medical technology and services company and the leader in real-world applications for AI Eye Screening™, announced today results of its expansion...